Title:
USE OF GP73 AS TREATMENT TARGET AND DIAGNOSTIC MARKER FOR NON-OBESE NON-ALCOHOLIC FATTY LIVER DISEASE
Document Type and Number:
WIPO Patent Application WO/2023/006127
Kind Code:
A1
Abstract:
The present application relates to a use of GP73 as a treatment target and a diagnostic marker for non-obese non-alcoholic fatty liver disease. GP73 promotes the occurrence and acceleration progress of non-obese NAFLD, and the inhibition of GP73 GAP enzyme activity effectively blocks the non-obese NAFLD phenotype induced by GP73.
Inventors:
LIN CHANGQING (CN)
GAO QI (CN)
SUN ZHIWEI (CN)
QIE SHUANG (CN)
XU LEI (CN)
LI JING (CN)
GAO QI (CN)
SUN ZHIWEI (CN)
QIE SHUANG (CN)
XU LEI (CN)
LI JING (CN)
Application Number:
PCT/CN2022/120727
Publication Date:
February 02, 2023
Filing Date:
September 23, 2022
Export Citation:
Assignee:
BEIJING SUNGEN BIOMEDICAL TECH CO LTD (CN)
International Classes:
A61K45/00; A61K39/395; A61P1/16; C12Q1/68
Foreign References:
| CN106405104A | 2017-02-15 | |||
| CN110088627A | 2019-08-02 | |||
| CN113144194A | 2021-07-23 | |||
| US20200338122A1 | 2020-10-29 |
Other References:
PENG YUMENG, ZENG QIANG, WAN LUMING, MA ENHAO, LI HUILONG, YANG XIAOPAN, ZHANG YANHONG, HUANG LINFEI, LIN HAOTIAN, FENG JIANGYUE, : "GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity", NATURE COMMUNICATIONS, vol. 12, no. 1, XP093029177, DOI: 10.1038/s41467-021-27309-1
Attorney, Agent or Firm:
BEIJING YUEHE INTELLECTUAL PROPERTY AGENCY CO. LTD (CN)
Download PDF: